
|Articles|June 1, 2004
Ruboxistaurin slows central DME, does not halt progression
Inhibition of PKC shown to affect changes in retinal blood flow as well as leukocyte adhesion
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Coave Therapeutics reveals lead gene therapy program, CoTx-10
2
Harrow completes acquisiton of Melt Pharmaceuticals
3
Opus Genetics doses first patient in phase 1/2 clinical trial, BIRD-1, evaluating OPGx-BEST1
4
Prolonged digital device use increases risk of headaches, eye pain, and fatigue in children
5


















































.png)


